

Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients

Mathilde Lamarque,^{1,2,3} Céline Bossard,⁴ Adrien Contejean,^{5,6} Pauline Brice,⁶ Marie Parrens,⁷ Steven Le Gouill,^{8,9} Josette Brière,¹⁰ Reda Bouabdallah,¹¹ Danielle Canioni,¹² Hervé Tilly,^{13,14} Brigitte Bouchindhomme,¹⁵ Emmanuel Bachy,^{16,17,18} Richard Delarue,¹⁹ Corinne Haioun,^{3,5,20} and Philippe Gaulard^{2,3,20}

[°]CH and PG contributed equally to this work

¹Institut IMAGINE, Unité INSERM U1163, Paris; ²Département de Pathologie, Groupe Henri-Mondor Albert-Chenevier, Assistance Publique – Hôpitaux de Paris, Créteil; ³Unité INSERM U955, Créteil; ⁴Service d'Anatomie et Cytologie Pathologiques, Centre Hospitalier Universitaire, Hôtel Dieu, Nantes; ⁵Unité Hémopathies Lymphoïdes, Groupe Henri Mondor Albert-Chenevier, Assistance Publique – Hôpitaux de Paris, Créteil; ⁶Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris; ⁷Département de Pathologie, Hôpital Pessac, Bordeaux; ⁸Service d'Hématologie Clinique, Unité d'Investigation Clinique, Centre Hospitalier Universitaire de Nantes; ⁹Unité INSERM, UMR892 - CNRS, UMR 6299, Université de Nantes; ¹⁰Département de Pathologie, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris; ¹¹Service d'onco-hématologie adulte, Institut Paoli-Calmettes, Marseille; ¹²Département de Pathologie, Hôpital Necker, Assistance Publique, Hôpitaux de Paris; ¹³Département d'hématologie clinique, Centre Henri Becquerel, Rouen; ¹⁴Unité INSERM U918, Centre Henri Becquerel, Rouen; ¹⁵Département de pathologie, CHU de Lille; ¹⁶Département d'hématologie clinique, Hospices Civils de Lyon, Université Claude Bernard Lyon-1, Pierre Bénite; ¹⁷Unité CNRS UMR5239, Lyon; ¹⁸Faculté de médecine Lyon Sud Charles Mérieux; ¹⁹Service d'Hématologie, Hôpital Necker, Assistance Publique, Hôpitaux de Paris, and ²⁰Université Paris Est, Créteil, France

Correspondence: philipe.gaulard@aphp.fr
doi:10.3324/haematol.2015.135400

Demographic data at BV initiation	Patients treated with BV monotherapy (N=56)
Age (years) : Median , Range	58 [19;83]
Sex : Male/female	37 (66%)/ 19 (34%)
Performance status 0-2 3-5 NA	17 (46%) 20 (54%) 19
Ann Arbor Stage I-II III-IV NA	8 (15%) 44 (85%) 4
Number of prior chemotherapy regimens Median [range]	3 [1;8]
Response to first line therapy Complete response / unconfirmed complete response Partial response Stable disease Progressive disease NA	26 (46.5%) 9 (16.1%) 1 (1.8%) 17 (30.4%) 3 (5.4%)
Disease status relative to most recent treatment line Refractory Relapse NA	32 (57.1%) 23 (41.1%) 1 (1.8%)
Prior autologous stem cell transplantation Prior allogeneic stem cell transplantation	8 (14%) 3 (5%)
Time since diagnosis (months, median [range]) Time since last line of treatment (months median [range])	18.41 [1.4; 164.1] 1.13 [0; 38.4]
PTCL subtypes Systemic ALCL Other non-ALCL systemic PTCL Primary cutaneous T-cell lymphomas	24 (43%) 14 (25%) 18 (32%)
CD30 expression Score 0 (<5%) Score I (5-24%) Score II (25-49%) Score III (50-75%) Score IV (>75%) NA	6 (13%) 4 (9%) 6 (13%) 6 (13%) 24 (52%) 10

Supplementary data

NA, not available